Show Stocks and Investing Publications • Mon, July 1, 2024
Christopher Raymond Maintained (TSHA) at Buy with Decreased Target to $7 on, Jul 1st, 2024
ymond-maintained-tsha-at-buy-with-decreased-target-to-7-on-jul-1st-2024.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIChristopher Raymond of Piper Sandler, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $9 to $7 on, Jul 1st, 2024.
Christopher has made no other calls on TSHA in the last 4 months.
There are 7 other peers that have a rating on TSHA. Out of the 7 peers that are also analyzing TSHA, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Christopher
- Keith Tapper of "BMO Capital" Initiated at Buy and Held Target at $5 on, Thursday, June 27th, 2024
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $7 on, Thursday, June 20th, 2024
- Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $5 on, Thursday, June 20th, 2024
- Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $7 on, Wednesday, June 19th, 2024
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy and Held Target at $7 on, Tuesday, June 18th, 2024
- Eun Yang of "Jefferies" Initiated at Strong Buy with Increased Target to $8 on, Tuesday, May 14th, 2024
- Whitney Ijem of "Canaccord Genuity" Reiterated at Strong Buy and Held Target at $7 on, Thursday, March 21st, 2024
Like: 👍